SEC
BCRX icon

Seven Eight Capital’s BioCryst Pharmaceuticals BCRX Stock Holding History

Seven Eight Capital’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-169,612
Closed -$1.05M – 719
2024
Q2 		$1.05M Buy
169,612
+158,358
+1,407% +$874K 0.11% 345
2024
Q1 		$57.2K Buy
+11,254
New +$63.3K 0.01% 582
2022
Q4 		– Sell
-20,330
Closed -$256K – 418
2022
Q3 		$256K Buy
+20,330
New +$262K 0.05% 412
2021
Q4 		– Sell
-50,132
Closed -$720K – 465
2021
Q3 		$720K Buy
50,132
+6,736
+16% +$106K 0.07% 363
2021
Q2 		$686K Buy
43,396
+11,596
+36% +$158K 0.1% 355
2021
Q1 		$237K Hold
31,800
– – 0.05% 353
2020
Q4 		$237K Buy
+31,800
New +$164K 0.05% 358

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

Seven Eight Capital's BCRX Position: Q3 2024 in Review

Seven Eight Capital sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2024, closing a stake of 169,612 shares — an estimated $1.05M sold.

Seven Eight Capital first reported a position in BCRX in Q4 2020 and held it in 7 quarters. The position peaked at $1.05M in Q2 2024. 257 funds tracked by Wall St. Rank hold BCRX as of Q3 2024.

  • Seven Eight Capital reported no remaining BioCryst Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Seven Eight Capital sold 169,612 BioCryst Pharmaceuticals shares in Q3 2024, an estimated $1.05M.
  • Seven Eight Capital first reported a position in BioCryst Pharmaceuticals in Q4 2020 and held it in 7 quarters.
  • Seven Eight Capital's BioCryst Pharmaceuticals position peaked at $1.05M in Q2 2024.
  • 257 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2024.

Based on Seven Eight Capital's 13F filing for Q3 2024, filed 12 Nov 2024.